The Research On The Effects Of The Combined Drug Treatment Of Rosuvastatin And Probucol In Anti-arotid Atherosclerosis

Objective：With the improvement of the living standard and the acceleration ofthe aging of population, the number of patients with hypertension,hyperlipidemia and diabetes is increased continuingly. These disease arethe main factors of AS. At the same time, AS, with high-rates ofmorbidity and mortality, is one of the main diseases threatening humanhealth worldwide. Inflammatory chemicals, blood lipid and blood glucoseplays important roles in the development of AS. The arotidatherosclerosis is one of the most common form of AS. And it is the mainfactor of cerebral infarction. The active treatment for arotidatherosclerosis is significant in reducing the rate of stroke and disability.An important method in anti-arotid atherosclerosis is to control the bloodlipids and reduce the damages of vascular endothelium caused byInflammatory chemicals.Statins is a kind of HMG-CoA, which is widely used for regulatingblood liquids in clinic. This drug could reduce the synthesis and secretionof lipoprotein, and have effects in stabling plaques, anti-inflammation andimproving endothelial function. The rosuvastatin is a new kind of Statins.Researches show that it could reduce the plaque size. The probucolis a kind of synthetic antioxidants, which has great effects in anti-arotidatherosclerosis,reducing inflammation, reducing cholesterol synthesis andpromoting cholesterol decomposition this paper is to investigate thatwether the combined drug treatment of rosuvastatin and probucol is better than the single drug treatment. The research chooses the patientswith carotid atherosclerosis, and applies the the combined drug treatmentof rosuvastatin and probucol for40weeks.Methods:To choose82patients who has been diagnosed carotidatherosclerosis,(Filter87cases, including5cases due to poor compliance,not opt-in),according to the carotid ultrasound examination confirmedboth carotid plaque concomitant patients with increased IMT thickness.The atherosclerotic plaque sick time is not limited to, male or female, age45-80years old, fasting blood glucose4.0-8.5mmol/L, blood pressure110-150/70-105mmHg, hyperlipidemia, carotid ultrasound shows IMT≥1.1mm and in patients with carotid artery plaque. Final selected82patients were randomly divided into A, B groups, Patients in Group Atake rosuvastatin10mg a time daily. Patients in Group B takerosuvastatin10mg a time daily and probucol0.5mg3times daily aftermeals. The duration of treatment was40weeks.To apply the software SPSS18.0in the statistical analysis of results.Using （x±s）to express the measurement data. The differences betweentwo groups were compared with t testResults:Rosuvastatin statin monotherapy group, after administration of TC,TG、 LDL-C, hs-CRP, carotid artery plaque size, IMT valuedecreased.After the combined drug treatment, the TC,TG、 LDL-C,hs-CRP,IMT, plaque size all reduced significantly. The difference arestatistically significant (P<0.05). No damages to the liver and kidney andother adverse reactions are observed during the treatment.Conclusions:Rosuvastatin combined with probucol reduce blood lipids, hs-CRP, reversal of carotid artery plaque size is better than rosuvastatinmonotherapy treatment,but blood pressure, fasting blood glucose did notchange significantly.